ClinicalTrials.gg
CompletedNCT02599324Updated Nov 18, 2023Results posted

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

A Phase 1/2 interventional study of ibrutinib and everolimus in Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma and Advanced Gastric Adenocarcinoma, sponsored by Pharmacyclics LLC.. Completed at 65 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
263
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,142 studies in Carcinoma, Renal Cell with a site in United States — 156 open to participants now, 280 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Enrollment
117th of 1,008
263 · median 40
Started
2015
with 41 others
Phase 1/2
146 of 1,142
31 open now
Registered
600th of 1,142
by date

Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, this one is the 117th largest by enrollment of the 1,008 interventional ones that give a count, is one of 42 that started in 2015, is one of 146 in phase 1/2, and was the 600th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

156 of the 1,142 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

151 more — sign in →

All 156 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,142 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advance gastrointestinal and genitourinary tumors.

03

Conditions studied

  • Metastatic Renal Cell Carcinoma
  • Advanced Urothelial Carcinoma
  • Advanced Gastric Adenocarcinoma
  • Metastatic Colorectal Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

RCC (clear cell), urothelial carcinoma (UC) (transitional cell), gastric or gastro-esophageal junctional (GEJ) adenocarcinoma, or K-RAS or N-RAS wild-type EGFR expressing CRC For cohort 1 RCC: minimum of 1 and maximum of 4 prior regimens, one or more of which must have included a VEGF-TKI For UC cohort 2: minimum of 1 and maximum of 2 prior regimens, one of which must have included a platinum-based regimen For UC cohort 5: Minimum of 1 and maximum of 2 prior regimens, one of which must have included a .

For UC cohort 6:

Locally advanced or mUC who are not eligible for cisplatin chemo with a PDL-1 score (CPS) of ≥ 10 without prior treatment.

Locally advanced or mUC who have progressed on platinum chemo or within 12 months of neo- or therapy with a platinum chemotherapy. A minimum of 1 and maximum of 2 prior therapies.

For cohort 3 gastric or GEJ adenocarcinoma: minimum of 1 and maximum of 3 prior regimens one of which must have included a fluoropyrimidine regimen For cohort 4 CRC: minimum of 2 and maximum of 4 prior regimens, which must have included both an irinotecan and an oxaliplatin based regimen unless unable to tolerate irinotecan chemotherapy

Laboratory:

Adequate hematologic function:

≥1500 cells/mm3 (1.5 x 109/L) count >80,000 cells/mm3 (80 x 109/L) for cohort 1 (RCC) Platelet counts >100,000 cells/mm3 (100 x 109/L) for all UC cohorts ≥8.0 g/dL. for cohort 1 (RCC),all UC cohorts, and cohort 3 (GC) Hemoglobin ≥9.0 g/dL for cohort 4 (CRC)

Adequate hepatic and renal function defined as:

Serum (AST) and/or alanine transaminase (ALT) ≤5.0 x (ULN) if liver , or ≤3 x ULN without liver metastases Alkaline phosphatase \<3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin, such as hemolysis) with the exception of subjects in the GC cohort where docetaxel is administered, these subjects must have bilirubin within normal limits (WNL) Estimated ≥30 mL/min (Cockcroft-Gault)

Exclusion criteria

Exclusion Criteria

Prior treatment with:

Everolimus or temsirolimus (RCC cohort 1) Any taxane (UC cohort of ibrutinib + paclitaxel) (cohort 2) (UC cohort 6) Any taxane (GC cohort 3) Cetuximab or panitumumab (CRC cohort 4)

For all Cohorts:

Concomitant use of warfarin or other Vitamin K antagonists History of stroke or intracranial hemorrhage within 6 months prior to enrollment Major surgery within 4 weeks of first dose of study drug Requires treatment with strong inhibitors known bleeding disorders or hemophilia

UC cohort 6 only:

Subjects who have an active, known or suspected disease. Evidence of interstitial lung disease or active, noninfectious pneumonitis.

Non- medications within 14 days before the first dose of ibrutinib and pembrolizumab.

Subjects in whom prior anti PD-1 / anti-PD-L1 therapy was intolerable and required discontinuation of treatment.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    Cohort 1: Renal Cell Carcinoma (RCC)

    Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of everolimus to determine the recommended phase 2 dose (RP2D) of ibrutinib. (The RP2D was determined for each cohort separately.) Phase 2: Participants receive ibrutinib at the RP2D determined in phase 1b in combination with everolimus.

    Drug: ibrutinib · Drug: everolimus

  • Experimental
    Cohort 2: Urothelial Carcinoma (UC)

    Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of paclitaxel to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.) Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with paclitaxel.

    Drug: ibrutinib · Drug: paclitaxel

  • Experimental
    Cohort 3: Gastric Adenocarcinoma (GA or GC)

    Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of docetaxel to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.) Phase 2: Participants receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel.

    Drug: ibrutinib · Drug: docetaxel

  • Experimental
    Cohort 4: Colorectal Adenocarcinoma (CRC)

    Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of cetuximab to determine RP2D of ibrutinib. (The RP2D was determined for each cohort separately.) Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab.

    Drug: ibrutinib · Drug: cetuximab

  • Experimental
    Cohort 5: Urothelial Carcinoma (UC) Ibrutinib

    Phase 1b: Participants receive ibrutinib at various dose levels to determine the RP2D of ibrutinib.(The RP2D was determined for each cohort separately.) Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b.

    Drug: ibrutinib

  • Experimental
    Cohort 6: Urothelial Carcinoma (UC) With Pembrolizumab

    Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of pembrolizumab to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.) Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with pembrolizumab.

    Drug: ibrutinib · Drug: pembrolizumab

Interventions

  • Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.

  • Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.

  • Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m\^2, once weekly, in continual 3 weekly cycles.

  • Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m\^2 (according to local institutional standard of care), given continually in 21-day cycles.

  • Cetuximab 400 mg/m\^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m\^2 infused over 60 minutes.

  • Pembrolizumab 200 mg intravenous (IV) every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cohorts 1 to 6

    A DLT was defined as any Grade 3 (severe) or higher non-hematologic or Grade 4 (life-threatening) hematologic adverse event (AE) occurring during the DLT observation period that was considered to be at least possibly related to the study treatment (ibrutinib or drug combination).

    Time frame: 21 days after the initiation of therapy at the start of Cycle 1

  2. Phase 1b/2 RP2D: Progression-Free Survival (PFS) as Assessed by Investigator in Cohorts 1 and 2

    PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of progressive disease (PD) or date of death from any cause, whichever occurs first, regardless of the use of subsequent anti-cancer treatment. PD was defined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study), and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.

    Time frame: Maximum time on study for Cohort 1 (Phase 1b/2 RP2D) was 37.4 months; for Cohort 2 (Phase 1b/2 RP2D) was 44.7 months.

  3. Phase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 6

    ORR is defined as the percentage of participants who have a best response of partial response (PR) or complete response (CR) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Maximum time on study (Phase 1b/2 RP2D) for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months.

Secondary outcomes

  1. Phase 1b: ORR in Cohorts 1 to 6

    ORR is defined as the percentage of participants who have a best response of partial response (PR) or complete response (CR) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Maximum time on study (Phase 1b only) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 34.2 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months.

  2. Phase 1b: Disease Control Rate (DCR) in Cohorts 1 to 6

    DCR is is defined as the percentage of participants who have a best response of PR, CR, or stable disease (SD) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after). For SD, tthere was no need for confirmation by a subsequent imaging assessment.

    Time frame: Maximum time on study (Phase 1b only) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 34.2 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months.

  3. Phase 1b/2 RP2D: DCR in Cohorts 1 to 6

    DCR is is defined as the percentage of participants who have a best response of PR, CR, or SD to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after). For SD, tthere was no need for confirmation by a subsequent imaging assessment.

    Time frame: Maximum time on study (Phase 1b/2 RP2D) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)

  4. Phase 1b/2 RP2D: PFS in Cohorts 3 to 6

    PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or date of death from any cause, whichever occurs first, regardless of the use of subsequent anti-cancer treatment. PD was defined in accordance with RECIST 1.1 criteria.

    Time frame: Maximum time on study (Phase 1b/2 RP2D) for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)

  5. Phase 1b/2 RP2D: ORR in Cohorts 1 and 2

    ORR is defined as the percentage of participants who have a best response to therapy of PR or CR in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Maximum time on study for Cohort 1 (Phase 1b/2 RP2D) was 37.4 months; for Cohort 2 (Phase 1b/2 RP2D) was 44.7 months. (Reverse Kaplan-Meier estimates)

  6. Phase 1b/2 RP2D: Overall Survival (OS) in Cohorts 1 to 6

    OS is defined as the time from the date of first dose of study treatment to the date of death from any cause. Subjects who were not known to have died at the data extraction will be censored at date last known alive.

    Time frame: Maximum time on study (Phase 1b/2 RP2D) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)

  7. Phase 1b/2 RP2D: Duration of Response (DOR) in Cohorts 1 to 6

    DOR is defined for confirmed responders (PR or better) as time from the date of initial response (PR or better) to the date of first documentation of PD (according to RECIST 1.1) or death, whichever occurs first, regardless of use of subsequent anti-cancer treatment. Confirmed responders without documentation of PD or death or with unknown status at the data extraction were censored at the last adequate post-baseline disease assessment showing no evidence of PD. PD was defined as at least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions. Per protocol, participants in Phase 1b receiving the Phase 2 RP2D and participants in Phase 2 RP2D were analyzed together.

    Time frame: Maximum time on study (Phase 1b/2 RP2D) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)

  8. Phase 1b: Observed Maximum Concentration (Cmax) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

    Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The Cmax was noted as observed.

    Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose

  9. Phase 1b: Time to Cmax (Tmax) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

    Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The tmax was noted as observed.

    Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose

  10. Phase 1b: Time of Last Observed Concentration (Tlast) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

    Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The tlast was noted as observed.

    Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose

  11. Phase 1b: Area Under the Concentration-Time Curve From Time 0 to Hour 24 (AUC0-24h) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

    Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The AUC0-24h was calculated by the linear trapezoidal method.

    Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose

  12. Phase 1b: Area Under the Concentration-Time Curve to Last Observed Time Point (AUClast) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

    Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The AUClast was calculated by the linear trapezoidal method.

    Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose

  13. Phase 1b: Terminal Elimination Half-Life (t1/2term) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

    Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The apparent t1/2term was calculated by ln(2)/λz, where λz is the apparent elimination rate constant obtained by linear regression of three or more log-transformed data points in the terminal phase (not including Cmax).

    Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose

  14. Phase 1b: Terminal Elimination Rate Constant (λz) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

    Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The λz is the apparent elimination rate constant obtained by linear regression of three or more log-transformed data points in the terminal phase (not including Cmax).

    Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose

  15. Phase 1b: Apparent Total Clearance at Steady-State (CLss/F) for Ibrutinib in Cohorts 1 to 4

    Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. Apparent total CLss/F (Cycle 2 Day 1) was calculated as dose/AUC0-24h.

    Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose

07

Results

Posted Oct 26, 2022

Participant flow

In Phase 1b, participants were enrolled into 6 separate cohorts according to clinical indication: renal cell carcinoma (RCC; Cohort 1), urothelial carcinoma (UC; Cohort 2), gastric adenocarcinoma (GA; Cohort 3), colorectal adenocarcinoma (CRC; Cohort 4), urothelial carcinoma (UC; Cohorts 5 and 6). A dose level review committee (DLRC) evaluated the safety data at the completion of Phase 1b in each cohort to determine the recommended Phase 2 dose (RP2D), with the exception of Cohort 5.

Phase 1b
Participant flow — Phase 1b
MilestoneCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab
Started37410218121017
Completed37410218121017
Not completed000000000
Phase 2 (RP2D)
Participant flow — Phase 2 (RP2D)
MilestoneCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab
Started038055310443313
Continued from phase 1b0606606812
Enrolled in phase 203204925039251
Enrolled and treated in phase 203204925038251
Completed038055310443313
Not completed000000000

Outcome measures

PrimaryPhase 1b: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cohorts 1 to 6

A DLT was defined as any Grade 3 (severe) or higher non-hematologic or Grade 4 (life-threatening) hematologic adverse event (AE) occurring during the DLT observation period that was considered to be at least possibly related to the study treatment (ibrutinib or drug combination).

Time frame:
21 days after the initiation of therapy at the start of Cycle 1
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cohorts 1 to 6
ParticipantsCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cohorts 1 to 6010020000
PrimaryPhase 1b/2 RP2D: Progression-Free Survival (PFS) as Assessed by Investigator in Cohorts 1 and 2

PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of progressive disease (PD) or date of death from any cause, whichever occurs first, regardless of the use of subsequent anti-cancer treatment. PD was defined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study), and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.

Time frame:
Maximum time on study for Cohort 1 (Phase 1b/2 RP2D) was 37.4 months; for Cohort 2 (Phase 1b/2 RP2D) was 44.7 months.
Reported as:
Median · months
Phase 1b/2 RP2D: Progression-Free Survival (PFS) as Assessed by Investigator in Cohorts 1 and 2
monthsCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 840 mg + Paclitaxel
Phase 1b/2 RP2D: Progression-Free Survival (PFS) as Assessed by Investigator in Cohorts 1 and 25.6 (3.9 to 7.5)4.1 (2.7 to 4.4)
PrimaryPhase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 6

ORR is defined as the percentage of participants who have a best response of partial response (PR) or complete response (CR) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Maximum time on study (Phase 1b/2 RP2D) for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months.
Reported as:
Number · percentage of participants
Phase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 6
percentage of participantsCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab
Phase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 617.9 (8.7 to 31.1)14.9 (7.2 to 26.2)6.9 (1.2 to 20.2)35.7 (15.3 to 61.0)
SecondaryPhase 1b: ORR in Cohorts 1 to 6

ORR is defined as the percentage of participants who have a best response of partial response (PR) or complete response (CR) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Maximum time on study (Phase 1b only) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 34.2 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months.
Reported as:
Number · percentage of participants
Phase 1b: ORR in Cohorts 1 to 6
percentage of participantsCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab
Phase 1b: ORR in Cohorts 1 to 60 (0.0 to 63.2)0 (0.0 to 34.8)50.0 (9.8 to 90.2)20.0 (3.7 to 50.7)11.1 (2.0 to 31.0)12.5 (0.6 to 47.1)0 (0.0 to 25.9)12.5 (0.6 to 47.1)38.5 (16.6 to 64.5)
SecondaryPhase 1b: Disease Control Rate (DCR) in Cohorts 1 to 6

DCR is is defined as the percentage of participants who have a best response of PR, CR, or stable disease (SD) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after). For SD, tthere was no need for confirmation by a subsequent imaging assessment.

Time frame:
Maximum time on study (Phase 1b only) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 34.2 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months.
Reported as:
Number · percentage of participants
Phase 1b: Disease Control Rate (DCR) in Cohorts 1 to 6
percentage of participantsCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab
Phase 1b: Disease Control Rate (DCR) in Cohorts 1 to 666.7 (13.5 to 98.3)71.4 (34.1 to 94.7)75.0 (24.9 to 98.7)50.0 (22.2 to 77.8)77.8 (56.1 to 92.0)75.0 (40.0 to 95.4)80.0 (49.3 to 96.3)37.5 (11.1 to 71.1)76.9 (50.5 to 93.4)
SecondaryPhase 1b/2 RP2D: DCR in Cohorts 1 to 6

DCR is is defined as the percentage of participants who have a best response of PR, CR, or SD to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after). For SD, tthere was no need for confirmation by a subsequent imaging assessment.

Time frame:
Maximum time on study (Phase 1b/2 RP2D) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)
Reported as:
Number · percentage of participants
Phase 1b/2 RP2D: DCR in Cohorts 1 to 6
percentage of participantsCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab
Phase 1b/2 RP2D: DCR in Cohorts 1 to 680.6 (66.6 to 90.5)66.7 (55.0 to 77.0)74.4 (60.4 to 85.4)83.0 (71.4 to 91.2)48.3 (32.0 to 64.8)71.4 (46.0 to 89.6)
SecondaryPhase 1b/2 RP2D: PFS in Cohorts 3 to 6

PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or date of death from any cause, whichever occurs first, regardless of the use of subsequent anti-cancer treatment. PD was defined in accordance with RECIST 1.1 criteria.

Time frame:
Maximum time on study (Phase 1b/2 RP2D) for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)
Reported as:
Median · months
Phase 1b/2 RP2D: PFS in Cohorts 3 to 6
monthsCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab
Phase 1b/2 RP2D: PFS in Cohorts 3 to 64.0 (2.7 to 4.2)5.4 (4.1 to 5.8)1.6 (1.4 to 2.5)2.9 (1.7 to NA)
SecondaryPhase 1b/2 RP2D: ORR in Cohorts 1 and 2

ORR is defined as the percentage of participants who have a best response to therapy of PR or CR in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Maximum time on study for Cohort 1 (Phase 1b/2 RP2D) was 37.4 months; for Cohort 2 (Phase 1b/2 RP2D) was 44.7 months. (Reverse Kaplan-Meier estimates)
Reported as:
Number · percentage of participants
Phase 1b/2 RP2D: ORR in Cohorts 1 and 2
percentage of participantsCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 840 mg + Paclitaxel
Phase 1b/2 RP2D: ORR in Cohorts 1 and 22.8 (0.1 to 12.5)26.3 (17.0 to 37.6)
SecondaryPhase 1b/2 RP2D: Overall Survival (OS) in Cohorts 1 to 6

OS is defined as the time from the date of first dose of study treatment to the date of death from any cause. Subjects who were not known to have died at the data extraction will be censored at date last known alive.

Time frame:
Maximum time on study (Phase 1b/2 RP2D) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)
Reported as:
Median · months
Phase 1b/2 RP2D: Overall Survival (OS) in Cohorts 1 to 6
monthsCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab
Phase 1b/2 RP2D: Overall Survival (OS) in Cohorts 1 to 621.0 (13.1 to 25.3)8.2 (6.2 to 10.3)7.3 (5.5 to 9.6)15.0 (10.5 to 17.2)8.2 (4.4 to NA)15.7 (7.7 to NA)
SecondaryPhase 1b/2 RP2D: Duration of Response (DOR) in Cohorts 1 to 6

DOR is defined for confirmed responders (PR or better) as time from the date of initial response (PR or better) to the date of first documentation of PD (according to RECIST 1.1) or death, whichever occurs first, regardless of use of subsequent anti-cancer treatment. Confirmed responders without documentation of PD or death or with unknown status at the data extraction were censored at the last adequate post-baseline disease assessment showing no evidence of PD. PD was defined as at least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions. Per protocol, participants in Phase 1b receiving the Phase 2 RP2D and participants in Phase 2 RP2D were analyzed together.

Time frame:
Maximum time on study (Phase 1b/2 RP2D) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)
Reported as:
Median · months
Phase 1b/2 RP2D: Duration of Response (DOR) in Cohorts 1 to 6
monthsCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab
Phase 1b/2 RP2D: Duration of Response (DOR) in Cohorts 1 to 63.1 (NA to NA)4.4 (3.1 to 6.8)5.5 (3.0 to 18.0)11.1 (4.2 to 12.5)3.5 (3.1 to NA)NA (2.6 to NA)
SecondaryPhase 1b: Observed Maximum Concentration (Cmax) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The Cmax was noted as observed.

Time frame:
Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Reported as:
Mean · ng/mL
Phase 1b: Observed Maximum Concentration (Cmax) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
ng/mLCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + Cetuximab
Ibrutininb172 ± 188351 ± 247260 ± 287424 ± 319164 ± 193172 ± 116371 ± 270
PCI-4522751.2 ± 50.0147 ± 77.6127 ± 74.0198 ± 106106 ± 64.6154 ± 76.1177 ± 98.9
SecondaryPhase 1b: Time to Cmax (Tmax) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The tmax was noted as observed.

Time frame:
Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Reported as:
Median · hours
Phase 1b: Time to Cmax (Tmax) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
hoursCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + Cetuximab
Ibrutininb3.01 (1.03 to 4.00)2.00 (0.933 to 5.90)3.71 (1.00 to 6.00)4.00 (0.833 to 6.00)3.89 (0.917 to 6.10)2.89 (1.00 to 4.08)2.03 (0.967 to 24.0)
PCI-452273.03 (1.03 to 6.02)3.93 (1.00 to 5.90)4.00 (2.00 to 6.00)4.00 (1.00 to 6.00)4.00 (0.917 to 6.10)2.99 (1.25 to 4.08)4.00 (0.967 to 24.0)
SecondaryPhase 1b: Time of Last Observed Concentration (Tlast) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The tlast was noted as observed.

Time frame:
Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Reported as:
Median · hours
Phase 1b: Time of Last Observed Concentration (Tlast) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
hoursCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + Cetuximab
Ibrutininb15.0 (5.92 to 24.0)24.0 (24.0 to 24.0)24.0 (6.00 to 24.0)24.0 (5.50 to 24.0)24.0 (5.75 to 24.0)24.0 (5.80 to 24.0)24.0 (5.42 to 24.0)
PCI-4522715.0 (5.92 to 24.0)24.0 (24.0 to 24.0)24.0 (6.00 to 24.0)24.0 (5.50 to 24.0)24.0 (5.85 to 24.0)24.0 (24.0 to 24.0)24.0 (5.75 to 24.0)
SecondaryPhase 1b: Area Under the Concentration-Time Curve From Time 0 to Hour 24 (AUC0-24h) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The AUC0-24h was calculated by the linear trapezoidal method.

Time frame:
Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Reported as:
Mean · ng∙h/mL
Phase 1b: Area Under the Concentration-Time Curve From Time 0 to Hour 24 (AUC0-24h) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
ng∙h/mLCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + Cetuximab
Ibrutininb1467 ± 17932568 ± 19682194 ± 30233503 ± 26131253 ± 1232980 ± 3712807 ± 1955
PCI-45227646 ± 6981810 ± 9451146 ± 7862604 ± 14351254 ± 7771527 ± 7172178 ± 1278
SecondaryPhase 1b: Area Under the Concentration-Time Curve to Last Observed Time Point (AUClast) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The AUClast was calculated by the linear trapezoidal method.

Time frame:
Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Reported as:
Mean · ng∙h/mL
Phase 1b: Area Under the Concentration-Time Curve to Last Observed Time Point (AUClast) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
ng∙h/mLCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + Cetuximab
Ibrutininb1316 ± 18502568 ± 19681180 ± 9253227 ± 24521107 ± 1178847 ± 3102647 ± 1967
PCI-45227548 ± 7411810 ± 945859 ± 7442380 ± 15611165 ± 8031527 ± 7172178 ± 1278
SecondaryPhase 1b: Terminal Elimination Half-Life (t1/2term) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The apparent t1/2term was calculated by ln(2)/λz, where λz is the apparent elimination rate constant obtained by linear regression of three or more log-transformed data points in the terminal phase (not including Cmax).

Time frame:
Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Reported as:
Mean · hours
Phase 1b: Terminal Elimination Half-Life (t1/2term) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
hoursCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + Cetuximab
IbrutininbNA ± NA6.28 ± 2.357.24 ± 2.364.31 ± 1.955.54 ± 1.75NA ± NA5.52 ± 1.26
PCI-45227NA ± NA8.00 ± 0.4895.08 ± 0.3046.79 ± 4.386.48 ± 2.118.10 ± NA8.02 ± 2.17
SecondaryPhase 1b: Terminal Elimination Rate Constant (λz) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4

Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The λz is the apparent elimination rate constant obtained by linear regression of three or more log-transformed data points in the terminal phase (not including Cmax).

Time frame:
Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Reported as:
Mean · 1/h
Phase 1b: Terminal Elimination Rate Constant (λz) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
1/hCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + Cetuximab
IbrutininbNA ± NA0.125 ± 0.04770.101 ± 0.03270.195 ± 0.09020.135 ± 0.0349NA ± NA0.132 ± 0.0296
PCI-45227—0.0870 ± 0.005350.137 ± 0.008490.149 ± 0.1030.118 ± 0.03990.0897 ± NA0.0942 ± 0.0336
SecondaryPhase 1b: Apparent Total Clearance at Steady-State (CLss/F) for Ibrutinib in Cohorts 1 to 4

Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. Apparent total CLss/F (Cycle 2 Day 1) was calculated as dose/AUC0-24h.

Time frame:
Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Reported as:
Mean · L/h
Phase 1b: Apparent Total Clearance at Steady-State (CLss/F) for Ibrutinib in Cohorts 1 to 4
L/hCohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + Cetuximab
Phase 1b: Apparent Total Clearance at Steady-State (CLss/F) for Ibrutinib in Cohorts 1 to 41103 ± 1370622 ± 647994 ± 12171067 ± 27421102 ± 1412645 ± 248595 ± 726

Adverse events

Collected over All-Cause Mortality: Maximum time on study (Phase 1b/2 RP2D) was 37.4 months, 44.7 months, 41.9 months, 23.5 months, 17.3 months, 20.1 months for Cohorts 1, 2, 3, 4, 5, 6 respectively. Serious/Other Adverse Events: First dose of study drug to end of treatment + 30 days. Mean time on treatment was: 14.5, 20.1, 16.3, 13.5, 12.8, 11.0, 10.9, 10.4, 15.8, 8.8, 13.5, 7.7, 8.4, 7.8, 9.2 months for the Reporting Groups presented below (from left to right), respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (RCC) Phase 1b: Ibrutinib 560 mg + Everolimus3/3 (100%)2/3 (66.7%)3/3 (100%)
Cohort 1 (RCC) Phase 1b: Ibrutinib 840 mg + Everolimus1/7 (14.3%)2/7 (28.6%)7/7 (100%)
Cohort 1 (RCC) Phase 2: Ibrutinib 840 mg + Everolimus22/38 (57.9%)18/38 (47.4%)34/38 (89.5%)
Cohort 2 (UC) Phase 1b: Ibrutinib 560 mg + Paclitaxel3/4 (75%)2/4 (50%)4/4 (100%)
Cohort 2 (UC) Phase 1b: Ibrutinib 840 mg + Paclitaxel4/10 (40%)5/10 (50%)10/10 (100%)
Cohort 2 (UC) Phase 2: Ibrutinib 840 mg + Paclitaxel51/55 (92.7%)32/55 (58.2%)51/55 (92.7%)
Cohort 3 (GA) Phase 1b: Ibrutinib 560 mg + Docetaxel13/21 (61.9%)15/21 (71.4%)20/21 (95.2%)
Cohort 3 (GA) Phase 2 (RP2D): Ibrutinib 560 mg + Docetaxel17/31 (54.8%)12/31 (38.7%)26/31 (83.9%)
Cohort 4 (CA) Phase 1b: Ibrutinib 560 mg + Cetuximab6/8 (75%)5/8 (62.5%)8/8 (100%)
Cohort 4 (CA) Phase 1b: Ibrutinib 840 mg + Cetuximab4/12 (33.3%)2/12 (16.7%)12/12 (100%)
Cohort 4 (CA) Phase 2 (RP2D): Ibrutinib 840 mg + Cetuximab31/44 (70.5%)14/44 (31.8%)40/44 (90.9%)
Cohort 5 (UC) Phase 1b: Ibrutinib 840 mg2/10 (20%)3/10 (30%)9/10 (90%)
Cohort 5 (UC) Phase 2: Ibrutinib 840 mg20/33 (60.6%)16/33 (48.5%)29/33 (87.9%)
Cohort 6 (UC) Phase 1b: Ibrutinib 560 mg + Pembrolizumab4/17 (23.5%)7/17 (41.2%)16/17 (94.1%)
Cohort 6 (UC) Phase 2: Ibrutinib 560 mg + Pembrolizumab3/13 (23.1%)3/13 (23.1%)7/13 (53.8%)
Most frequent serious events
Showing 10 of 144
Most frequent serious events
EventCohort 1 (RCC) Phase 1b: Ibrutinib 560 mg + EverolimusCohort 1 (RCC) Phase 1b: Ibrutinib 840 mg + EverolimusCohort 1 (RCC) Phase 2: Ibrutinib 840 mg + EverolimusCohort 2 (UC) Phase 1b: Ibrutinib 560 mg + PaclitaxelCohort 2 (UC) Phase 1b: Ibrutinib 840 mg + PaclitaxelCohort 2 (UC) Phase 2: Ibrutinib 840 mg + PaclitaxelCohort 3 (GA) Phase 1b: Ibrutinib 560 mg + DocetaxelCohort 3 (GA) Phase 2 (RP2D): Ibrutinib 560 mg + DocetaxelCohort 4 (CA) Phase 1b: Ibrutinib 560 mg + CetuximabCohort 4 (CA) Phase 1b: Ibrutinib 840 mg + CetuximabCohort 4 (CA) Phase 2 (RP2D): Ibrutinib 840 mg + CetuximabCohort 5 (UC) Phase 1b: Ibrutinib 840 mgCohort 5 (UC) Phase 2: Ibrutinib 840 mgCohort 6 (UC) Phase 1b: Ibrutinib 560 mg + PembrolizumabCohort 6 (UC) Phase 2: Ibrutinib 560 mg + Pembrolizumab
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/30/70/380/41/101/557/214/310/80/120/440/100/330/170/13
ACUTE CORONARY SYNDROMECardiac disorders1/30/70/380/40/100/550/210/310/80/120/440/100/330/170/13
CARDIAC FAILURE CONGESTIVECardiac disorders1/30/70/380/40/100/550/210/310/80/120/440/100/330/170/13
DIARRHOEAGastrointestinal disorders1/31/70/380/40/101/550/211/310/80/120/440/100/330/170/13
AMYLOIDOSISImmune system disorders1/30/70/380/40/100/550/210/310/80/120/440/100/330/170/13
RESPIRATORY TRACT INFECTIONInfections and infestations1/31/70/380/40/100/550/211/310/80/120/440/100/330/170/13
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/30/71/380/40/100/550/210/310/81/120/440/100/330/170/13
ACUTE KIDNEY INJURYRenal and urinary disorders1/31/71/380/40/102/550/210/310/80/120/440/101/331/170/13
RENAL FAILURERenal and urinary disorders1/30/70/380/40/100/550/211/310/80/120/440/101/330/170/13
INTERSTITIAL LUNG DISEASERespiratory, thoracic and mediastinal disorders1/30/70/380/40/100/550/210/310/80/120/440/100/330/170/13
Most frequent other events
Showing 10 of 258
Most frequent other events
EventCohort 1 (RCC) Phase 1b: Ibrutinib 560 mg + EverolimusCohort 1 (RCC) Phase 1b: Ibrutinib 840 mg + EverolimusCohort 1 (RCC) Phase 2: Ibrutinib 840 mg + EverolimusCohort 2 (UC) Phase 1b: Ibrutinib 560 mg + PaclitaxelCohort 2 (UC) Phase 1b: Ibrutinib 840 mg + PaclitaxelCohort 2 (UC) Phase 2: Ibrutinib 840 mg + PaclitaxelCohort 3 (GA) Phase 1b: Ibrutinib 560 mg + DocetaxelCohort 3 (GA) Phase 2 (RP2D): Ibrutinib 560 mg + DocetaxelCohort 4 (CA) Phase 1b: Ibrutinib 560 mg + CetuximabCohort 4 (CA) Phase 1b: Ibrutinib 840 mg + CetuximabCohort 4 (CA) Phase 2 (RP2D): Ibrutinib 840 mg + CetuximabCohort 5 (UC) Phase 1b: Ibrutinib 840 mgCohort 5 (UC) Phase 2: Ibrutinib 840 mgCohort 6 (UC) Phase 1b: Ibrutinib 560 mg + PembrolizumabCohort 6 (UC) Phase 2: Ibrutinib 560 mg + Pembrolizumab
DIARRHOEAGastrointestinal disorders2/35/716/384/48/1036/5514/2110/312/86/1219/440/1010/338/170/13
FATIGUEGeneral disorders0/33/714/383/45/1015/558/218/312/88/1214/441/109/336/174/13
ALOPECIASkin and subcutaneous tissue disorders0/30/70/383/43/1015/556/218/311/80/123/440/100/330/170/13
DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders1/32/75/381/41/106/551/212/314/88/1231/440/100/330/170/13
DECREASED APPETITEMetabolism and nutrition disorders0/34/713/382/47/1018/558/2110/313/85/129/444/108/331/171/13
ANAEMIABlood and lymphatic system disorders2/32/719/381/44/1020/558/2116/311/81/125/440/106/330/170/13
STOMATITISGastrointestinal disorders2/33/720/381/43/1014/559/218/314/85/1220/440/103/334/170/13
OEDEMA PERIPHERALGeneral disorders2/30/78/382/41/1014/554/212/314/83/124/442/104/333/170/13
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/30/73/380/40/101/551/210/311/80/120/440/100/331/170/13
BLOOD CREATININE INCREASEDInvestigations2/31/77/381/41/100/550/210/310/80/122/440/101/331/170/13

Baseline characteristics

All treated population: all unique participants enrolled and treated in Phase 1b and Phase 2.

Age, Customized
Age, Customized(Participants)Cohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + PembrolizumabTotal
18 - 64 years12332133625116129
65 - 84 years216135132252212128
≥ 85 years0003000205
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + PembrolizumabTotal
Female1808127219571
Male231451341292613191
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + PembrolizumabTotal
Hispanic or Latino00247301118
Not Hispanic or Latino339255394503417243
Unknown or Not Reported0000010001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (RCC): Ibrutinib 560 mg + EverolimusCohort 1 (RCC): Ibrutinib 840 mg + EverolimusCohort 2 (UC): Ibrutinib 560 mg + PaclitaxelCohort 2 (UC): Ibrutinib 840 mg + PaclitaxelCohort 3 (GA): Ibrutinib 560 mg + DocetaxelCohort 4 (CRC): Ibrutinib 560 mg + CetuximabCohort 4 (CRC): Ibrutinib 840 mg + CetuximabCohort 5 (UC): Ibrutinib 840 mgCohort 6 (UC): Ibrutinib 560 mg + PembrolizumabTotal
American Indian or Alaska Native0000000011
Asian07012122315069
Native Hawaiian or Other Pacific Islander0000000000
Black or African American0000111014
White332447325183016187
More than one race0000000000
Unknown or Not Reported0000100001
08

Study locations

65 sites
  • Clearview Cancer Institute /ID# 1128-0965
    Huntsville, Alabama 35805, United States
  • Banner MD Anderson Cancer Center /ID# 1128-0802
    Gilbert, Arizona 85234, United States
  • University of Arizona Cancer Center - Tucson /ID# 1128-1546
    Tucson, Arizona 85724, United States
  • Alta Bates Comprehensive Cancer Center /ID# 1128-0135
    Berkeley, California 94704, United States
  • St Marys Medical Center /ID# 1128-0969
    Daly City, California 94015, United States
  • Duplicate_University of California San Diego/ Moores Cancer Center /ID# 1128-0241
    La Jolla, California 92037-0845, United States
  • VA Long Beach Healthcare System /ID# 1128-0480
    Long Beach, California 90822-5201, United States
  • USC Norris Cancer Center /ID# 1128-0209
    Los Angeles, California 90033, United States
  • UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 1128-0008
    Orange, California 92868-3201, United States
  • Gregory Smith, MD (Private Practice) /ID# 1128-0419
    Saint Helena, California 94574, United States
  • Salinas Valley Memorial Hosp /ID# 1128-0482
    Salinas, California 93901, United States
  • Premiere Oncology, A Medical Corporation /ID# 1128-1085
    Santa Monica, California 90404, United States
  • St. Joseph Health /ID# 1128-1462
    Santa Rosa, California 95403, United States
  • Whittingham Cancer Center at Norwalk Hospital /ID# 1128-0411
    Norwalk, Connecticut 06856-3852, United States
  • Georgetown University Hospital /ID# 1128-0824
    Washington, District of Columbia 20007, United States
  • Duplicate_Cancer Specialist of North Florida (CSNF) ( R ) /ID# 1128-1093
    Jacksonville, Florida 32207, United States
  • IACT Health-Columbus /ID# 1128-1389
    Columbus, Georgia 31904-8946, United States
  • Northshore Kellogg Cancer Center /ID# 1128-0484
    Evanston, Illinois 60201, United States
  • Franciscan Health Indianapolis /ID# 1128-1125
    Indianapolis, Indiana 46237, United States
  • Horizon Oncology Research Center /ID# 1128-0337
    Lafayette, Indiana 47905, United States
  • University of Iowa Hospitals and Clinics /ID# 1128-0766
    Iowa City, Iowa 52242, United States
  • The University of Kansas Cancer Center /ID# 1128-0706
    Fairway, Kansas 66205, United States
  • East Jefferson General Hospital /ID# 1128-1084
    Metairie, Louisiana 70006, United States
  • Duplicate_Tufts Medical Center /ID# 1128-0016
    Boston, Massachusetts 02111-1552, United States
  • Barbara Ann Karmanos Cancer In /ID# 1128-0130
    Detroit, Michigan 48201, United States
  • Henry Ford Hospital /ID# 1128-0195
    Detroit, Michigan 48202, United States
  • Central Care Cancer Center /ID# 1128-1596
    Bolivar, Missouri 65613, United States
  • Capital Region Medical Center /ID# 1128-1412
    Jefferson City, Missouri 65102, United States
  • Nebraska Methodist Hospital /ID# 1128-0229
    Omaha, Nebraska 68114, United States
  • New Jersey Center for Cancer Research /ID# 1128-0493
    Brick, New Jersey 08724, United States
  • Duplicate_New Mexico Cancer Care Alliance /ID# 1128-0938
    Albuquerque, New Mexico 87106, United States
  • San Juan Oncology Associates /ID# 1128-1020
    Farmington, New Mexico 87401, United States
  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 1128-0091
    New York, New York 10065-6007, United States
  • Wake Forest Univ HS /ID# 1128-0975
    Winston-Salem, North Carolina 27157, United States
  • Oregon Health & Science University /ID# 1128-0251
    Portland, Oregon 97239-3011, United States
  • Penn State Hershey Medical Ctr /ID# 1128-0220
    Hershey, Pennsylvania 17033-2360, United States
  • Abramson Cancer Center of the Univ. of Pennsylvania /ID# 1128-0402
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt Infectious Disease Clinic /ID# 1128-0024
    Nashville, Tennessee 37232, United States
  • The University of Texas Medical Branch (UTMB) - Cancer Center - Galves /ID# 1128-0974
    Galveston, Texas 77555-0565, United States
  • Duplicate_Scott & White Mem Hosp & Clin /ID# 1128-0046
    Temple, Texas 76508, United States
  • Duplicate_Virginia Cancer Specialists - Fairfax Office /ID# 1128-0972
    Fairfax, Virginia 22031, United States
  • Virginia Mason Medical Center /ID# 1128-0005
    Seattle, Washington 98101, United States
  • University of Washington /ID# 1128-1382
    Seattle, Washington 98109, United States
  • Confluence Health /ID# 1128-0894
    Wenatchee, Washington 98801, United States
  • Seoul National University Bundang Hospital /ID# 1128-0982
    Seongnam, Gyeonggido 13620, Korea, Republic of
  • Yonsei University Health System Severance Hospital /ID# 1128-0927
    Seoul, Seoul Teugbyeolsi 03722, Korea, Republic of
  • Chonnam National University Hwasun Hospital /ID# 1128-0916
    Jeonnam, 58128, Korea, Republic of
  • Seoul National University Hospital /ID# 1128-0926
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center /ID# 1128-0963
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center /ID# 1128-0925
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital /ID# 1128-0928
    Seoul, 06591, Korea, Republic of
  • Korea University Guro Hospital /ID# 1128-0924
    Seoul, 08308, Korea, Republic of
  • Instituto Catalan de Oncologia (ICO) Badalona /ID# 1128-0984
    Badalona, Barcelona 08916, Spain
  • Hospital Unversitario Marques de Valdecilla /ID# 1128-0973
    Santander, Cantabria 39008, Spain
  • Hospital Universitario Vall d'Hebron /ID# 1128-0534
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona /ID# 1128-0533
    Barcelona, 08036, Spain
  • Hospital Universitario Ramon y Cajal /ID# 1128-0874
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre /ID# 1128-0864
    Madrid, 28041, Spain
  • Hospital Universitario La Paz /ID# 1128-0921
    Madrid, 28046, Spain
  • Hospital Universitario Virgen del Rocio /ID# 1128-0863
    Sevilla, 41013, Spain
  • Sarah Cannon Research Institute /ID# 1128-1079
    London, England W1G 6AD, United Kingdom
  • Duplicate_Beatson west of scotland cancer center /ID# 1128-0652
    Glasgow, Scotland G12 0YN, United Kingdom
  • The Royal Marsden NHS Foundation Trust /ID# 1128-0543
    London, SW3 6JJ, United Kingdom
  • The Christie Hospital /ID# 1128-0030
    Manchester, M20 4BX, United Kingdom
  • Duplicate_Oxford University Hospitals NHS Trust /ID# 1128-0814
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Data sharing details ↗ · yoda.yale.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Aug 2021, 68 months.

Results were first posted in Oct 2022, 1 year 2 months after primary completion. A results delay was requested in Mar 2022.

Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 68 months is close to that.

Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2015
First posted
Nov 6, 2015
StartActual
Dec 1, 2015
Primary completionActual
Aug 20, 2021
CompletionActual
Aug 20, 2021
Results delay requested
Mar 22, 2022
Results first posted
Oct 26, 2022
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02599324
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Nov 6, 2015
Start date
Dec 1, 2015
Primary completion
Aug 20, 2021
Completion
Aug 20, 2021
Results posted
Oct 26, 2022
Last update
Nov 18, 2023

Study contacts

Pharmacyclics LLC
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion